In a significant shift in global health dynamics, tuberculosis (TB) has reclaimed its position as the world’s new leading infectious killer, surpassing COVID-19. According to the World Health Organization (WHO), TB caused approximately 1.25 million deaths in 2023, overtaking the mortality rate of COVID-19 for the first time since the pandemic began .
Understanding Tuberculosis: New Leading Infectious Killer
Tuberculosis is caused by the bacterium Mycobacterium tuberculosis, primarily affecting the lungs but capable of impacting other parts of the body. It spreads through airborne particles when an infected person coughs or sneezes. Despite being preventable and treatable, TB remains a significant global health challenge.
In 2023, an estimated 10.8 million people contracted TB, marking the highest number since WHO began global monitoring in 1995 . While the number of TB-related deaths slightly decreased from 1.32 million in 2022 to 1.25 million in 2023, the overall disease burden remains substantial.
Factors Contributing to the Resurgence of TB
Several factors have contributed to the resurgence of tuberculosis as the leading infectious killer:
- Disruption of Health Services: The COVID-19 pandemic strained healthcare systems worldwide, leading to reduced TB detection and treatment services.
- Delayed Diagnoses: Lockdowns and fear of contracting COVID-19 deterred individuals from seeking medical care, resulting in delayed TB diagnoses and treatment.
- Drug Resistance: The emergence of multidrug-resistant TB strains poses significant treatment challenges, requiring longer and more complex therapy regimens.
- Socioeconomic Factors: Poverty, malnutrition, and crowded living conditions, especially in low- and middle-income countries, facilitate the spread of TB.
Global Distribution and High-Burden Countries
TB cases are not evenly distributed globally. In 2023, 87% of infections occurred in just 30 countries, with India, Indonesia, China, the Philippines, and Pakistan accounting for 56% of the global burden . These high-burden countries face challenges such as limited healthcare infrastructure, high population densities, and socioeconomic disparities that exacerbate TB transmission.
The Intersection of TB and HIV
TB is a leading cause of death among people living with HIV, due to their compromised immune systems. In 2023, approximately 161,000 TB deaths occurred among HIV-positive individuals . Integrated approaches to address both TB and HIV are crucial in reducing mortality rates.
The Challenge of Antimicrobial Resistance
Antimicrobial resistance (AMR) is a growing concern in TB treatment. Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) are more difficult and costly to treat, with lower success rates. AMR threatens to undermine progress made in TB control and requires urgent attention to develop new diagnostics, drugs, and vaccines.
Strategies for Combating TB
To address the resurgence of tuberculosis, a multifaceted approach is necessary:
- Strengthening Health Systems: Investing in healthcare infrastructure to improve TB detection, diagnosis, and treatment services.
- Enhancing Surveillance: Implementing robust monitoring systems to track TB cases and resistance patterns.
- Promoting Research and Development: Supporting the development of new TB diagnostics, treatments, and vaccines to combat drug-resistant strains.
- Addressing Social Determinants: Improving living conditions, nutrition, and access to healthcare to reduce TB transmission.
- Integrating TB and HIV Services: Coordinating care for individuals with TB and HIV to improve outcomes.
Conclusion
The re-emergence of tuberculosis as the world’s leading infectious killer underscores the need for renewed global commitment to TB control. By addressing healthcare disparities, investing in research, and strengthening health systems, the international community can work towards reducing the burden of TB and preventing further loss of life.
Sou
IFLScience
kncvtbc.org
PMC